Bios Clinical Opportunity Fund, LP — SEC insider filings

SEC reporting owner CIK 1988639. 7 insider filings on record with FilingPulse; latest filed 2026-10-30.

Transaction summary — filings shown

Covers all 7 filings on record, filed 2024-08-14 to 2026-10-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
ACTUATE THERAPEUTICS, INC. (ACTU)Director, 10% owner53 legs · 571,428 sh · $4,499,9966 legs · 49,998 sh · $424,98365
IN8BIO, INC. (INAB)10% owner2——7

Insider filings — Bios Clinical Opportunity Fund, LP

FiledFormIssuerReported transactionsSource
2026-10-304ACTUATE THERAPEUTICS, INC. (ACTU)
jointly with BIOS Fund I, LP, Bios 2024 Co-Invest, LP, BIOS Actuate Co-Invest I, LP, BIOS Actuate Co-Invest II, LP, Bios Actuate Co-Invest III, LP, BIOS Fund I QP, LP, BIOS Fund II NT, LP, BIOS Fund II QP, LP, BIOS Fund II, LP
Grant/award (A): 64,995 (derivative) @ $0 · Grant/award (A): 87,743 (derivative) @ $0 · Grant/award (A): 682,885 (derivative) @ $0 · Grant/award (A): 194,984 (derivative) @ $0 · Grant/award (A): 368,304 (derivative) @ $0 · Grant/award (A): 47,972 (derivative) @ $0 · +7 moreEDGAR
2025-06-304ACTUATE THERAPEUTICS, INC. (ACTU)
jointly with Bios Equity COF, LP, Bios 2024 Co-Invest, LP, BP Directors, LP
Purchase (P): 71,428 @ $7 · Purchase (P): 71,428 (derivative) @ $0EDGAR
2025-05-074IN8BIO, INC. (INAB)
jointly with Fletcher Aaron G.L., BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Bios Equity COF, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC
Purchase (P): 1,148,482 (derivative) · Other (J): 574,241 (derivative) · Other (J): 574,241 (derivative)EDGAR
2024-10-114IN8BIO, INC. (INAB)
jointly with Fletcher Aaron G.L., BIOS Fund II, LP, BIOS Fund II QP, LP, BIOS Fund II NT, LP, BIOS Incysus Co-Invest I, LP, Bios Equity COF, LP, BIOS Capital Management, LP, BIOS Advisors GP, LLC
Purchase (P): 709,040 (derivative) · Purchase (P): 709,040 (derivative) · Disposition to issuer (D): 574,241 (derivative) · Grant/award (A): 574,241 (derivative)EDGAR
2024-08-204/AACTUATE THERAPEUTICS, INC. (ACTU)
jointly with Bios Equity COF, LP, BP Directors, LP
Sale (S): 5,314 @ $8 · Sale (S): 17,361 @ $8 · Sale (S): 2,324 @ $8EDGAR
2024-08-144ACTUATE THERAPEUTICS, INC. (ACTU)
jointly with Bios Equity COF, LP, BP Directors, LP
Conversion (C): 884,427 · Purchase (P): 375,000 @ $8 · Purchase (P): 125,000 @ $8 · Conversion (C): 525,797 · Conversion (C): 307,538 · Conversion (C): 141,457 · +50 moreEDGAR
2024-08-144ACTUATE THERAPEUTICS, INC. (ACTU)
jointly with Bios Equity COF, LP, BP Directors, LP
Holdings only — no transactions reportedEDGAR

FilingPulse's Form 4 archive currently extends back to 2021-07-14 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1988639 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs